Xiangliang Yang

Nov 4, 2024 | nature.com | Jingjie Liu |Tuying Yong |Ben Zhao |Shenghong Ju |Gao-Jun Teng |Xiangliang Yang

AbstractNerve–cancer crosstalk has gained substantial attention owing to its impact on tumour growth, metastasis and therapy resistance. Effective therapeutic strategies targeting tumour-associated nerves within the intricate tumour microenvironment remain a major challenge in pancreatic cancer.

Sep 13, 2023 | nature.com | Tuying Yong |Xiaoping Chen |Xiangliang Yang

AbstractThe durable response rate to immune checkpoint blockade such as anti-programmed cell death-1 (PD-1) antibody remains relatively low in hepatocellular carcinoma (HCC), mainly depending on an immunosuppressive microenvironment with limited number of CD8+ T cells, especially stem-like CD8+ T cells, in tumor tissues.

Mar 15, 2023 | nature.com | Xiangliang Yang

AbstractNanomedicine has been developed for cancer therapy over several decades, while rapid clearance from blood circulation by reticuloendothelial system (RES) severely limits nanomedicine antitumour efficacy. We design a series of nanogels with distinctive stiffness and investigate how nanogel mechanical properties could be leveraged to overcome RES.